The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer
β Scribed by G. J. van Londen; S. Perera; K. Vujevich; P. Rastogi; B. Lembersky; A. Brufsky; V. Vogel; S. L. Greenspan
- Publisher
- Springer US
- Year
- 2010
- Tongue
- English
- Weight
- 261 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. In this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole. ## METHODS. Two hundred twentyβsix pa
## Abstract ## BACKGROUND. Over the past decade, a number of new therapeutic agents have become available in the treatment of metastatic breast cancer (MBC). This study characterized the use and assessed the impact on survival of populationβbased access to new agents for the treatment of MBC. ##